Evidence map›Paper›PMID 39468304›Full record

ArticleCellular & molecular immunology2024

Glut3 promotes cellular O-GlcNAcylation as a distinctive tumor-supportive feature in Treg cells.

Amit Sharma, Garima Sharma, Zhen Gao, Ke Li, Mutong Li, Menglin Wu, Chan Johng Kim, Yingjia Chen, Anupam Gautam, Hong Bae Choi and 9 more

Abstract read
In one paragraph

Article in Cellular & molecular immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. GLUT1 expression, lymphocyte distribution and CD3Journal of experimental & clinical cancer research : CR · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Amit SharmaDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.ORCID 0000-0002-8109-1690
Garima Sharma *Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.
Zhen Gao *School of Life Science & Technology, ShanghaiTech University, Shanghai, 201210, China.
Ke LiSchool of Life Science & Technology, ShanghaiTech University, Shanghai, 201210, China.
Mutong LiSchool of Life Science & Technology, ShanghaiTech University, Shanghai, 201210, China.
Menglin WuSchool of Life Science & Technology, ShanghaiTech University, Shanghai, 201210, China.
Chan Johng KimDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.
Yingjia ChenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Anupam GautamInstitute for Bioinformatics and Medical Informatics, University of Tübingen, Sand 14, Tübingen, 72076, Germany.ORCID 0000-0002-6460-6525
Hong Bae ChoiDaehang Hospital, Seoul, 06699, Republic of Korea.
Jin KimDepartment of Surgery, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Jung-Myun KwakDepartment of Surgery, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Sin Man LamState Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology Chinese Academy of Sciences, Beijing, 100101, China.
Guanghou ShuiState Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology Chinese Academy of Sciences, Beijing, 100101, China.ORCID 0000-0002-1621-9643
Sandip PaulCenter for Health Science and Technology, JIS Institute of Advanced Studies and Research, JIS University, Kolkata, 700091, India.ORCID 0000-0001-7406-3598
Yongqiang FengDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Keunsoo KangDepartment of Microbiology, College of Natural Sciences, Dankook University, Cheonan, 31116, Republic of Korea.ORCID 0000-0003-0611-9320
Sin-Hyeog ImDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea. iimsh@postech.ac.kr.ORCID 0000-0002-3173-1856
Dipayan RudraDepartment of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea. drudra@shanghaitech.edu.cn.

Funding

National Research Foundation of Korea (NRF) 4.24643.01
6 · The paper itself

Abstract

Regulatory T cells (Tregs) establish dominant immune tolerance but obstruct tumor immune surveillance, warranting context-specific mechanistic insights into the functions of tumor-infiltrating Tregs (TIL-Tregs). We show that enhanced posttranslational O-linked N-acetylglucosamine modification (O-GlcNAcylation) of cellular factors is a molecular feature that promotes a tumor-specific gene expression signature and distinguishes TIL-Tregs from their systemic counterparts. We found that altered glucose utilization through the glucose transporter Glut3 is a major facilitator of this process. Treg-specific deletion of Glut3 abrogates tumor immune tolerance, while steady-state immune homeostasis remains largely unaffected in mice. Furthermore, by employing mouse tumor models and human clinical data, we identified the NF-κB subunit c-Rel as one such factor that, through Glut3-dependent O-GlcNAcylation, functionally orchestrates gene expression in Tregs at tumor sites. Together, these results not only identify immunometabolic alterations and molecular events contributing to fundamental aspects of Treg biology, specifically at tumor sites but also reveal tumor-specific cellular properties that can aid in the development of Treg-targeted cancer immunotherapies.

Indexed as

Glucose Transporter Type 3T-Lymphocytes, RegulatoryAcetylglucosamineAnimalsGlucoseHumansImmune ToleranceLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLNeoplasmsAcetylglucosamineGlucoseGlucose Transporter Type 3Glut3O-GlcNAcylationRegulatory T cellsTregTreg metabolism

Identifiers

PMID39468304
PMCPMC11606946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.